interferon gamma-1b

Actimmune, Immukin (UK)

Pharmacologic class: Biological response modifier

Therapeutic class: Antineoplastic

Pregnancy risk category C


Enhances cellular toxicity and killer cell activity and promotes generation of oxygen metabolites in phagocytes, resulting in destruction of microorganisms.


Injection: 100 mcg (2 million international units)/0.5-ml vial

Indications and dosages

Chronic granulomatous disease; severe malignant osteoperosis

Adults with body surface area (BSA) above 0.5 m2: 50 mcg/m2 (1 million international units/m2) subcutaneously three times weekly

Adults with BSA of 0.5 m2 or less: 1.5 mcg/kg subcutaneously three times weekly in deltoid or anterior thigh


• Hypersensitivity to drug, its components, or Escherichia coli-derived products


Use cautiously in:
• thyroid disorders, bone marrow depression, hepatic or cardiac disease, seizure disorders, compromised CNS function
• pregnant or breastfeeding patients
• children ages 18 and younger.


• Administer into deltoid muscle by subcutaneous route only.
• Give at bedtime if flulike symptoms occur.
• Provide antiemetics to ease nausea and vomiting, as prescribed.

Adverse reactions

CNS: dizziness, confusion, paresthesia, lethargy, depression, difficulty thinking or concentrating, insomnia, anxiety, fatigue, amnesia, nervousness, drowsiness, asthenia, malaise

CV: chest pain, hypertension, palpitations, arrhythmias

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, pancreatitis

GU: proteinuria

Hematologic: anemia, leukopenia, thrombocytopenia, neutropenia

Musculoskeletal: joint pain, back pain, myalgia

Skin: flushing, rash, dry skin, erythema

Other: flulike symptoms, weight loss, edema, hypersensitivity reaction


Drug-drug.Bone marrow depressants: increased bone marrow depression

Zidovudine: increased zidovudine blood level

Drug-diagnostic tests.Hepatic enzymes: increased levels

Neutrophils, platelets: decreased counts

Patient monitoring

Before and monthly during therapy, assess CBC with white cell differential, glucose and electrolyte levels, and liver and kidney function tests.
• Assess fluid intake and output. Keep patient well hydrated.
• Monitor for GI upset. Provide small, frequent meals or antiemetics to ease severe nausea and vomiting.

Monitor patient for mental status changes and depression.
• Assess for flulike symptoms. If these occur, give drug at bedtime and provide supportive care, such as rest and acetaminophen for headache and fever.

Patient teaching

• Teach patient or caregiver how to administer drug subcutaneously, rotate injection sites, and track dosing schedule and injection sites on calendar.

Tell patient to contact prescriber immediately if depression occurs.
• Advise patient to eat small, frequent meals to combat nausea, vomiting, and appetite loss.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Inform female patient that drug is linked to fetal abnormalities. Advise her not to get pregnant during therapy, and to use barrier contraception.
• Tell female patient to consult prescriber before breastfeeding.
• Tell patient he'll need regular follow-up examinations and blood tests to monitor drug effects.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

interferon gamma-1b

(in-ter-feer-on) ,


(trade name)


Therapeutic: immune modifiers
Pharmacologic: interferons
Pregnancy Category: C


Diminished severity and frequency of infectious complications of chronic granulomatous disease.Slow disease progression in severe, malignant osteopetrosis.


A protein produced by recombinant DNA technology that is capable of activating phagocytes, enhancing their ability to kill pathogens, including:
  • Staphylococcus aureus,
  • Toxoplasma gondii,
  • Leishmania donovani,
  • Listeria monocytogenes,
  • Mycobacterium avium intracellulare.
Interferon gamma has antiproliferative effects superior to interferon alpha and beta.

Therapeutic effects

Decreased incidence and severity of infection in patients with chronic granulomatous disease.
Slowed disease progression of severe, malignant osteopetrosis.


Absorption: Well absorbed after subcut administration.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: 5.9 hr.

Time/action profile (blood levels)

Subcutunknown4 hrunknown


Contraindicated in: Hypersensitivity to interferon gamma, Escherichia coli–derived products, mannitol, or polysorbate.
Use Cautiously in: cardiovascular disease; Bone marrow depression; Pregnancy, lactation, or children <1 yr (safety not established).

Adverse Reactions/Side Effects

Central nervous system

  • headache (most frequent)
  • decreased mental status
  • dizziness


  • nausea (most frequent)
  • vomiting (most frequent)
  • abdominal pain


  • rash (most frequent)


  • neutropenia
  • thrombocytopenia


  • edema or tenderness at injection site (most frequent)


  • arthralgia (most frequent)
  • myalgia (most frequent)
  • back pain


  • gait disturbances


  • chills (most frequent)
  • fever (most frequent)


Drug-Drug interaction

May have additive bone marrow–depressing effects with antineoplastics or radiation therapy.


Body Surface Area >0.5 m2
Subcutaneous (Children) 50 mcg/m2 (1 million units/m2) 3 times weekly.
Body Surface Area ≤0.5 m2
Subcutaneous (Children >1 yr) 1.5 mcg/kg 3 times weekly.


Injection: 100 mcg (3 million units)/vial

Nursing implications

Nursing assessment

  • Assess patient for signs and symptoms of infection before and throughout therapy. Flu-like syndrome (fever, headache, chills, myalgia, fatigue) is a frequent side effect that may decrease in severity as treatment continues. Side effects may be minimized by administering at bedtime. Headache and fever may be treated with acetaminophen. If adverse reactions are severe, dose may be reduced by 50% or discontinued.
  • Lab Test Considerations: Monitor CBC with differential, platelet count, blood chemistries including liver and kidney function, and urinalysis before and every 3 mo throughout therapy.

Potential Nursing Diagnoses

Risk for infection (Indications)


  • Vial must be refrigerated; do not freeze. If vial is left at room temperature for more than 12 hr, discard vial. Vials do not contain a preservative and are for single use only. Do not shake.
  • Subcutaneous: Administer in the right or left arm or anterior thigh.

Patient/Family Teaching

  • Home Care Issues: Instruct patient or family on proper technique for administering injection and care and disposal of equipment. Provide a puncture-proof container for disposal of needles.
    • Advise patient of the need for contraception throughout therapy.

Evaluation/Desired Outcomes

  • Decrease in frequency and severity of infections in patients with chronic granulomatous disease.
  • Slowed disease progression in severe, malignant osteopetrosis.


A bioengineered form of interferon gamma, which acts as a biologic response modifier by stimulating the human immune system. It is approved by the FDA for patients with chronic granulomatous disease (CGD) and severe, malignant osteopetrosis.
References in periodicals archive ?
4-1BBL, 506U78, Actimmune, Ad-IFNg, AlloMune, AMD-3100, Aplidin, ASIbcl, Atragen, Avastin, BCX1777, B-E8, Beta LT, Bexxar, Caelyx, Calsed, Campath, Clofarabine, CMC-544, CpG-7909, Depocyte, Edodekin Alpha, Elsamitrucin, FAVID, Fludara, FR-901228, Ganite, GEMZAR, GENASENSE, GRN163, GTI-2040, GTOP-99, hA20, HMR1275, HSPPC-96, Hu1D10, hum291, HuMax, IDEC-114, IDEC-152, IDIOVAX, Intron A, INX-3280, ISF-154, KiroMAb, LY317615, Lymphocide, Lymphorad131, MDX-060, MGV, Midostaurin, MT103, NIPENT, NOVATRONE, Oncolym, OncoTCS, Ontak, Orathecin Rubitecan, Parlodel, PEGIntron, Porleukin, Pretarget Lymphoma, PRO64553, Product R, Prothecan, Remitogen, Rituxan, SGN-30, SGN-35, T-900607, TH9402, Thalidomid, Trap, TRISENOX, UCN-01, VAXID, VB2-011, VEGF Trap, VELCADE, Zevalin
Actimmune revenue in the second quarter of 2007 was approximately 40% lower than in the same quarter of 2006, reflecting lower off-label physician prescriptions of Actimmune for the treatment of idiopathic pulmonary fibrosis (IPF), which InterMune does not promote.
Other cancer vaccine strategies that are on the way are Actimmune, Allovectin-7, Avicine, BEC2, Canvaxin, CeaVac, Gastrimmune, GMK, LymphoCide, Melacine, Ovarex, Oncophage, Osidem and.
PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in thousands, except per share amounts) Three Months Ended March 31 2007 2006 Revenue, net Actimmune $19,525 $24,356 Collaboration revenue 818 - Total revenue, net 20,343 24,356 Costs and expenses: Cost of goods sold 5,284 6,373 Research and development 29,439 21,561 General and administrative 9,496 10,705 Restructuring charges 1,333 - Total costs and expenses 45,552 38,639 Loss from operations (25,209) (14,283) Interest income 2,700 2,142 Interest expense (714) (314) Other income (expense) 2,562 (77) Loss from continuing operations (20,661) (12,532) Discontinued operations: Loss from discontinued operations (144) (254) Net loss $(20,805) $(12,786) Basic and diluted net loss per share: Continuing operations $(0.
Specifically, the complaint alleges that defendants were aware that demand for Actimmune was declining because: (1) the most recent clinical study showed that Actimmune was not effective in the treatment of certain pulmonary diseases, (2) Actimmune inventory levels were increasing, and (3) doctor demand was falling due, in part, to the Company's decision to curtail physician education, the lifeblood of InterMune's off-label sales of Actimmune.
The complaint alleges that defendants made false and misleading statements about one of the Company's leading products, Actimmune.
His landmark lawsuit alleges that InterMune, basically a one-product company - the product is Actimmune -- has unlawfully suppressed a life-saving drug, Pirfenidone, in order to protect its Actimmune market from competition of the cheaper, more effective drug.
An amended complaint filed in San Francisco on March 20, 2003 details extensive violations by InterMune of the Sherman Act, clear breaches of FDA rules about promoting 'off label' uses of Actimmune for IPF, and blatant manipulation of the IPF community by payments to doctors.
InterMune sells an interferon gamma drug called Actimmune for the treatment of IPF.
Nevertheless, Actimmune is still a very encouraging treatment for IPF patients and the company expects continued strong growth of the drug to push total revenue in 2002 to the upper end of its $105 million to $110 million range.
in a cash-and-stock deal, expanding its product portfolio with the addition of the immune system disorder drug Actimmune.
NASDAQ: ITMN) today announced that on June 19, 2012, the company completed the previously announced sale of its rights to Actimmune (interferon gamma-1b) to Vidara Therapeutics International Limited (Vidara).